{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T20:21:34Z","timestamp":1787948494164,"version":"build-2784847793"},"reference-count":37,"publisher":"Jaypee Brothers Medical Publishing","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.59556\/japi.72.0480","type":"journal-article","created":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T06:43:24Z","timestamp":1752216204000},"page":"75-78","source":"Crossref","is-referenced-by-count":3,"title":["A Review of Olmesartan-based Therapy in Targeting Effective Blood Pressure Control and Achieving Blood Pressure Goals"],"prefix":"10.59556","volume":"72","author":[{"given":"Mangesh","family":"Tiwaskar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ketan K","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabhu","family":"Kasture","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2914","reference":[{"issue":"(6):","key":"key20250711064320_B1","doi-asserted-by":"crossref","first-page":"e12471.","DOI":"10.1111\/1755-5922.12471","article-title":"Management of arterial hypertension with angiotensin receptor blockers: current evidence and the role of olmesartan.","volume":"36","author":"Omboni","year":"2018;","journal-title":"Cardiovasc Ther"},{"issue":"(11):","key":"key20250711064320_B2","doi-asserted-by":"crossref","first-page":"868\u2013","DOI":"10.1161\/CIRCULATIONAHA.121.054602","article-title":"Harmonization of the American College of Cardiology\/American Heart Association and European Society of Cardiology\/European Society of Hypertension Blood Pressure\/Hypertension Guidelines: comparisons, reflections, and recommendations.","volume":"146","author":"Whelton","year":"2022;","journal-title":"Circulation"},{"issue":"(6):","key":"key20250711064320_B3","doi-asserted-by":"crossref","first-page":"579\u2013","DOI":"10.1159\/000518812","article-title":"Hypertension Clinical Practice Guidelines (ISH, 2020): what is new?","volume":"30","author":"Chakraborty","year":"2021;","journal-title":"Med Princ Pract"},{"issue":"(11):","key":"key20250711064320_B4","doi-asserted-by":"crossref","first-page":"745\u2013","DOI":"10.1038\/s41371-020-0349-x","article-title":"Indian guidelines on hypertension-IV (2019).","volume":"34","author":"Shah","year":"2020;","journal-title":"J Hum Hypertens"},{"key":"key20250711064320_B5","doi-asserted-by":"crossref","first-page":"507\u2013","DOI":"10.2147\/VHRM.S337640","article-title":"Angiotensin receptor blockers in the management of hypertension: a real-world perspective and current recommendations.","volume":"18:","author":"Gallo","year":"2022;","journal-title":"Vasc Health Risk Manag"},{"key":"key20250711064320_B6","doi-asserted-by":"crossref","first-page":"1\u2013","DOI":"10.4137\/CMT.S2206","article-title":"Hypertension: Focus on olmesartan medoxomil.","volume":"1:","author":"Bell","year":"2009:","journal-title":"Clin Med Therapeutics"},{"issue":"(3):","key":"key20250711064320_B7","doi-asserted-by":"crossref","first-page":"255\u2013","DOI":"10.1007\/s40292-021-00443-z","article-title":"Arb-based combination therapy for the clinical management of hypertension and hypertension-related comorbidities: a spotlight on their use in COVID-19 patients.","volume":"28","author":"Presta","year":"2021;","journal-title":"High Blood Press Cardiovasc Prev"},{"issue":"(1):","key":"key20250711064320_B8","doi-asserted-by":"crossref","first-page":"13\u2013","DOI":"10.1007\/s40119-017-0087-5","article-title":"Management of hypertension using olmesartan alone or in combination.","volume":"6","author":"Zhang","year":"2017;","journal-title":"Cardiol Ther"},{"issue":"(6):","key":"key20250711064320_B9","first-page":"1866\u2013","article-title":"Interactions between antihypertensive drugs and food.","volume":"27","author":"J\u00e1uregui-Garrido","year":"2012;","journal-title":"Nutr Hosp"},{"issue":"(1):","key":"key20250711064320_B10","first-page":"22\u2013","article-title":"Use of angiotensin receptor blockers in cardiovascular protection current evidence and future directions.","volume":"36","author":"Munger","year":"2011;","journal-title":"P T"},{"issue":"(7):","key":"key20250711064320_B11","first-page":"464\u2013","article-title":"Angiotensin receptor blockers - advantages of the new sartans.","volume":"61","author":"Al Sabbah","year":"2013;","journal-title":"J Assoc Physicians India"},{"issue":"(10):","key":"key20250711064320_B12","doi-asserted-by":"crossref","first-page":"907\u2013","DOI":"10.1056\/NEJMoa1007994","article-title":"Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes.","volume":"364","author":"Haller","year":"2011;","journal-title":"N Engl J Med"},{"key":"key20250711064320_B13","first-page":"113\u2013","article-title":"Impact of olmesartan on blood pressure, endothelial function, and cardiovascular outcomes.","volume":"3:","author":"Pimenta","year":"2010;","journal-title":"Integr Blood Press Control"},{"issue":"(3):","key":"key20250711064320_B14","doi-asserted-by":"crossref","first-page":"165\u2013","DOI":"10.1016\/j.jash.2007.11.001","article-title":"Reversal of vascular hypertrophy in hypertensive patients through blockade of angiotensin II receptors.","volume":"2","author":"Smith","year":"2008;","journal-title":"J Am Soc Hypertens"},{"issue":"(2):","key":"key20250711064320_B15","doi-asserted-by":"crossref","first-page":"97\u2013","DOI":"10.1177\/1753944707085982","article-title":"Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study.","volume":"1","author":"Stumpe","year":"2007;","journal-title":"Ther Adv Cardiovasc Dis"},{"issue":"(3):","key":"key20250711064320_B16","doi-asserted-by":"crossref","first-page":"340\u2013","DOI":"10.1016\/j.ihj.2014.05.002","article-title":"WIN OVER study: Efficacy and safety of olmesartan in indian hypertensive patients: results of an open label, non-comparative, multi-centric, post marketing observational study.","volume":"66","author":"Kumbla","year":"2014;","journal-title":"Indian Heart J"},{"issue":"(8):","key":"key20250711064320_B17","doi-asserted-by":"crossref","first-page":"545\u2013","DOI":"10.2165\/00044011-200727080-00003","article-title":"Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST Study.","volume":"27","author":"Barrios","year":"2007;","journal-title":"Clin Drug Investig"},{"issue":"(2):","key":"key20250711064320_B18","doi-asserted-by":"crossref","first-page":"e000810.","DOI":"10.1161\/JAHA.114.000810","article-title":"The Randomized Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) observational follow-up study: benefits of RAS blockade with olmesartan treatment are sustained after study discontinuation.","volume":"3","author":"Menne","year":"2014;","journal-title":"J Am Heart Assoc"},{"issue":"(3):","key":"key20250711064320_B19","first-page":"e168\u2013","article-title":"Comparative safety and efficacy of topical mometasone furoate with other topical corticosteroids.","volume":"59","author":"Spada","year":"2018;","journal-title":"Australas J Dermatol"},{"issue":"(3):","key":"key20250711064320_B20","first-page":"106\u2013","article-title":"Efficacy and tolerability of olmesartan, telmisartan, and losartan in patients of stage i hypertension: a randomized, open-label study.","volume":"8","author":"Kalikar","year":"2017;","journal-title":"J Pharmacol Pharmacother"},{"issue":"(1):","key":"key20250711064320_B21","doi-asserted-by":"crossref","first-page":"7\u2013","DOI":"10.1291\/hypres.31.7","article-title":"Comparison of effects of olmesartan and telmisartan on blood pressure and metabolic parameters in Japanese early-stage type-2 diabetics with hypertension.","volume":"31","author":"Nakayama","year":"2008;","journal-title":"Hypertens Res"},{"key":"key20250711064320_B22","doi-asserted-by":"crossref","first-page":"62\u2013","DOI":"10.1016\/j.curtheres.2013.02.002","article-title":"Olmesartan is more effective than other angiotensin receptor antagonists in reducing proteinuria in patients with chronic kidney disease other than diabetic nephropathy.","volume":"74:","author":"Ono","year":"2013;","journal-title":"Curr Ther Res Clin Exp"},{"issue":"(6):","key":"key20250711064320_B23","doi-asserted-by":"crossref","first-page":"1034\u2013","DOI":"10.1111\/bcp.12569","article-title":"Safety of olmesartan in a patient with telmisartan-induced myotoxicity: a case report.","volume":"79","author":"Barvaliya","year":"2015;","journal-title":"Br J Clin Pharmacol"},{"issue":"(5):","key":"key20250711064320_B24","doi-asserted-by":"crossref","first-page":"578\u2013","DOI":"10.1016\/j.clinthera.2005.05.006","article-title":"Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.","volume":"27","author":"Ruilope","year":"2005;","journal-title":"Clin Ther"},{"issue":"(9):","key":"key20250711064320_B25","doi-asserted-by":"crossref","first-page":"836\u2013","DOI":"10.1038\/hr.2014.26","article-title":"Efficacy of olmesartan\/amlodipine combination therapy in reducing ambulatory blood pressure in moderate-to-severe hypertensive patients not controlled by amlodipine alone.","volume":"37","author":"Bilo","year":"2014;","journal-title":"Hypertens Res"},{"issue":"(5):","key":"key20250711064320_B26","doi-asserted-by":"crossref","first-page":"265\u2013","DOI":"10.1016\/j.kjms.2012.09.005","article-title":"Efficacy and tolerability between an olmesartan\/amlodipine fixed-dose combination and an amlodipine double dose in mild to moderate hypertension.","volume":"29","author":"Lin","year":"2013;","journal-title":"Kaohsiung J Med Sci"},{"issue":"(3):","key":"key20250711064320_B27","doi-asserted-by":"crossref","first-page":"252\u2013","DOI":"10.1016\/j.amjhyper.2003.11.003","article-title":"Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide.","volume":"17","author":"Chrysant","year":"2004;","journal-title":"Am J Hypertens"},{"issue":"(10):","key":"key20250711064320_B28","doi-asserted-by":"crossref","first-page":"649\u2013","DOI":"10.1007\/BF03261919","article-title":"Efficacy and safety of triple antihypertensive therapy with the olmesartan\/amlodipine\/hydrochlorothiazide combination.","volume":"32","author":"Volpe","year":"2012;","journal-title":"Clin Drug Investig"},{"issue":"(8):","key":"key20250711064320_B29","doi-asserted-by":"crossref","first-page":"3500\u2013","DOI":"10.1007\/s12325-020-01404-z","article-title":"Real-World Effectiveness and Safety of a Single-Pill Combination of Olmesartan\/Amlodipine\/Hydrochlorothiazide in Korean Patients with Essential Hypertension (RESOLVE): a large, observational, retrospective, cohort study.","volume":"37","author":"Park","year":"2020;","journal-title":"Adv Ther"},{"issue":"(1):","key":"key20250711064320_B30","doi-asserted-by":"crossref","first-page":"5\u2013","DOI":"10.1111\/jch.14700","article-title":"Efficacy and safety of olmesartan medoxomil-amlodipine besylate tablet in Chinese patients with essential hypertension: a prospective, single-arm, multi-center, real-world study.","volume":"26","author":"Cui","year":"2024;","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"(7):","key":"key20250711064320_B31","doi-asserted-by":"crossref","first-page":"1252\u2013","DOI":"10.1016\/j.clinthera.2010.07.008","article-title":"Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: the TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study.","volume":"32","author":"Oparil","year":"2010;","journal-title":"Clin Ther"},{"issue":"(1):","key":"key20250711064320_B32","doi-asserted-by":"crossref","first-page":"31\u2013","DOI":"10.1177\/1753944711432902","article-title":"Olmesartan\/amlodipine: blood pressure lowering and beyond in special populations.","volume":"6","author":"Erdine","year":"2012;","journal-title":"Ther Adv Cardiovasc Dis"},{"issue":"(3):","key":"key20250711064320_B33","doi-asserted-by":"crossref","first-page":"125\u2013","DOI":"10.3390\/ph2030125","article-title":"Combination therapy with olmesartan and amlodipine in the treatment of hypertension.","volume":"2","author":"Niemeijer","year":"2009;","journal-title":"Pharmaceuticals (Basel)"},{"issue":"(4):","key":"key20250711064320_B34","doi-asserted-by":"crossref","first-page":"587\u2013","DOI":"10.1016\/j.clinthera.2008.04.002","article-title":"The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study.","volume":"30","author":"Chrysant","year":"2008;","journal-title":"Clin Ther"},{"issue":"(6):","key":"key20250711064320_B35","doi-asserted-by":"crossref","first-page":"1237\u2013","DOI":"10.2147\/VHRM.S3642","article-title":"Clinical efficacy and safety of olmesartan\/hydrochlorothiazide combination therapy in patients with essential hypertension.","volume":"4","author":"Ruilope","year":"2008;","journal-title":"Vasc Health Risk Manag"},{"issue":"(4):","key":"key20250711064320_B36","doi-asserted-by":"crossref","first-page":"401\u2013","DOI":"10.2147\/vhrm.2006.2.4.401","article-title":"Olmesartan medoxomil combined with hydrochlorothiazide for the treatment of hypertension.","volume":"2","author":"Greathouse","year":"2006;","journal-title":"Vasc Health Risk Manag"},{"issue":"(1):","key":"key20250711064320_B37","doi-asserted-by":"crossref","first-page":"60\u2013","DOI":"10.1111\/jch.12621","article-title":"Adding hydrochlorothiazide to olmesartan\/amlodipine increases efficacy in patients with inadequate blood pressure control on dual-combination therapy.","volume":"18","author":"Rump","year":"2016;","journal-title":"J Clin Hypertens (Greenwich)"}],"container-title":["Journal of the Association of Physicians of India"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T06:43:31Z","timestamp":1752216211000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.japi.org\/article\/japi-72-3-75"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.59556\/japi.72.0480"],"URL":"https:\/\/doi.org\/10.59556\/japi.72.0480","relation":{},"ISSN":["0004-5772"],"issn-type":[{"value":"0004-5772","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]}}}